Press Releases


GW Pharmaceuticals Receives Orphan Drug Designation from FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy

24 April 2015

London, UK; 24 April 2015: GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Cannabidiol (C... more

GW Pharmaceuticals Announces New Physician Reports of Epidiolex® Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy

22 April 2015

... more

GW Pharmaceuticals Provides Update on Epidiolex® Program in Treatment-Resistant Childhood Epilepsies

8 January 2015

All trials on track or ahead of schedule with Phase 3 data now expected by end 2015... more